FDA Lifts Clinical Hold on Key Phase 3 Trial; Expands ATM Program to $400M

summarizeSummary

Intellia Therapeutics received FDA clearance to resume its MAGNITUDE Phase 3 trial for ATTR-CM and simultaneously expanded its ATM program to allow for the sale of up to $400 million in common stock.

check_boxKey Events

• FDA Lifts Clinical Hold on MAGNITUDE Phase 3 Trial

  The U.S. Food and Drug Administration (FDA) has removed the clinical hold on the MAGNITUDE Phase 3 clinical trial for nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This allows the trial to resume enrollment after a hold imposed in October 2025 due to a serious adverse event.

• ATM Offering Program Expanded to $400 Million

  Intellia amended its At-The-Market (ATM) Sales Agreement, increasing the total program size from $750 million to $1,035,316,650. This makes up to $400 million in common stock available for sale through Jefferies LLC, representing a highly dilutive potential offering.

auto_awesomeAnalysis

Intellia Therapeutics announced the FDA has lifted the clinical hold on its MAGNITUDE Phase 3 trial for nexiguran ziclumeran in ATTR-CM, a significant de-risking event for a critical pipeline asset. This follows the lift of the MAGNITUDE-2 trial hold in January. The company has aligned with the FDA on mitigation measures to enhance patient safety and resume enrollment. Concurrently, Intellia expanded its At-The-Market (ATM) offering program, increasing the total available for sale to $400 million. While the ATM provides substantial financial flexibility and extends the company's cash runway, it also represents a highly dilutive potential offering. The market reaction will likely balance the positive clinical progress against the potential dilutive impact of future share sales.